Key clinical point: Among patients with chronic myeloid leukemia (CML), the mean daily dose of nilotinib, either as the first- or second-line treatment prescribed in Italian clinical practice settings, was lower than the approved dose reported in the summary of product characteristics as the first- (600 mg daily) and second-line (800 mg daily) treatment.
Major finding: Based on the last determination of the BCR/ABL test, the mean daily nilotinib dose was 498.54 mg ( mean treatment duration, 811 days ) and 565.2 mg ( mean treatment duration, 323.1 days ) for patients treated with first- and second-line nilotinib, respectively.
Study details: Findings are from a retrospective analysis of adult patients with CML receiving either first-line nilotinib between January 2013 and December 2016 (n=87) or second-line nilotinib between January 2015 and December 2018 (n=103).
Disclosures: This publication was funded by Novartis Farma S.p.A. The authors declared no conflicts of interest.
Source: Perrone V et al. Ther Clin Risk Manag. 2021 Jun 8. doi: 10.2147/TCRM.S309342 .